Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)



Status:Completed
Conditions:Metabolic
Therapuetic Areas:Pharmacology / Toxicology
Healthy:No
Age Range:Any
Updated:3/6/2019
Start Date:March 12, 2015
End Date:November 24, 2018

Use our guide to learn which trials are right for you!

A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

UX023-CL203 is a Phase 2b, open-label, long-term extension study. The study will be conducted
in adults to assess the safety and pharmacodynamics of KRN23 administered via subcutaneous
injections monthly (every 4 weeks) for a total of 68 weeks. The study will enroll
approximately 25 adults with XLH who participated in Kyowa Hakko Kirin Pharma, Inc.'s (KHK's)
study KRN23-INT-001 or KRN23-INT-002. Subjects will need to discontinue oral phosphate and
vitamin D metabolite therapy prior to enrollment and throughout the duration of the study.


Inclusion Criteria:

1. Have participated in KHK's KRN23-INT-001 or KRN23-INT-002 studies (received at least 2
doses of KRN23)

2. Estimated glomerular filtration rate (eGFR) ≥60 mL/min at Screening.

3. Sexually active subjects must be willing to use an acceptable method of contraception
(e.g., double barrier method) while participating in the study and for 30 days after
receiving the last dose of KRN23.

Exclusion Criteria:

1. Subject experienced a safety-related event in the KRN23-INT-001 or KRN23-INT-002 study
that, in the opinion of the investigator and sponsor, precludes resuming KRN23
treatment.

2. Presence of nephrocalcinosis on renal ultrasound that, in the opinion of the
investigator and sponsor, precludes resuming KRN23 treatment.

3. Pregnant or breastfeeding at Screening or planning to become pregnant (self or
partner) at any time during the study.

4. Participation in an investigational drug or device trial within 30 days of enrollment
(other than KRN23-INT-001 or KRN23-INT-002).

5. Use of a pharmacologic vitamin D metabolite or analog (e.g., calcitriol,
doxercalciferol, and paricalcitol), phosphate, or aluminum hydroxide antacids (e.g.,
Maalox® and Mylanta®) within 21 days prior to Screening or during the study.

6. Use of medication to suppress PTH (e.g., Sensipar®, cinacalcet, calcimimetics) within
2 months prior to Screening.
We found this trial at
5
sites
550 University Boulevard
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials